{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:38:36Z","timestamp":1786541916513,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-55458-0","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:36:22Z","timestamp":1780385782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in peripheral blood T lymphocyte subsets before and after systemic therapy in patients with HER2-positive advanced breast cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Shu","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqiu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"3","key":"55458_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10911-020-09460-5","volume":"25","author":"B TO","year":"2020","unstructured":"TO, B., ISAAC, D. & RECHEK, E. R. Studying lymphatic metastasis in breast cancer: current models, strategies, and clinical perspectives. J. Mammary Gland Biol. 25 (3), 191\u2013203. https:\/\/doi.org\/10.1007\/s10911-020-09460-5 (2020).","journal-title":"J. Mammary Gland Biol."},{"issue":"4","key":"55458_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"M Sandra","year":"2020","unstructured":"Sandra, M. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomized, placebo-controlled, phase 3 study. Lancet Oncol. 21 (4), 519\u2013530. https:\/\/doi.org\/10.1016\/S1470-2045(19)30863-0 (2020).","journal-title":"Lancet Oncol."},{"issue":"11","key":"55458_CR3","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s11864-023-01137-5","volume":"24","author":"M Stanowicka-Grada","year":"2023","unstructured":"Stanowicka-Grada, M. & Senkus, E. Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer. Curr. Treat. Options Oncol. 24 (11), 1633\u20131650. https:\/\/doi.org\/10.1007\/s11864-023-01137-5 (2023).","journal-title":"Curr. Treat. Options Oncol."},{"issue":"11","key":"55458_CR4","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni, D., Angell, H. K. & Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer. 20 (11), 662\u2013680. https:\/\/doi.org\/10.1038\/s41568-020-0285-7 (2020).","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"55458_CR5","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1007\/s12094-023-03080-1","volume":"25","author":"Y Sun","year":"2023","unstructured":"Sun, Y. et al. The prognostic values of FOXP3\u2009+\u2009tumor-infiltrating T cells in breast cancer: a systematic review and meta-analysis. Clin. Transl Oncol. 25 (6), 1830\u20131843. https:\/\/doi.org\/10.1007\/s12094-023-03080-1 (2023).","journal-title":"Clin. Transl Oncol."},{"key":"55458_CR6","doi-asserted-by":"publisher","unstructured":"Angelico, G. et al. Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist\u2019s Perspective. Cancers (Basel). 15(18), 4479, (2023). https:\/\/doi.org\/10.3390\/cancers15184479. (2023).","DOI":"10.3390\/cancers15184479"},{"key":"55458_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.breast.2020.11.006","volume":"55","author":"XR Liu","year":"2021","unstructured":"Liu, X. R., Yu, J. J., Song, G. H., Li-Jun Di, H. F. & Jiang, Y. Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer. Breast 55, 7\u201315. https:\/\/doi.org\/10.1016\/j.breast.2020.11.006 (2021).","journal-title":"Breast"},{"issue":"1","key":"55458_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12282-016-0698-z","volume":"24","author":"S Burugu","year":"2017","unstructured":"Burugu, S., Asleh-Aburaya, K. & Nielsen, T. O. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer. 24 (1), 3\u201315. https:\/\/doi.org\/10.1007\/s12282-016-0698-z (2017).","journal-title":"Breast Cancer"},{"issue":"3","key":"55458_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1080\/08830185.2017.1401620","volume":"37","author":"BK Banin-Hirata","year":"2018","unstructured":"Banin-Hirata, B. K. et al. The prognostic value of regulatory T cells infiltration in HER2-enriched breast cancer microenvironment. Int. Rev. Immunol. 37 (3), 144\u2013150. https:\/\/doi.org\/10.1080\/08830185.2017.1401620 (2018).","journal-title":"Int. Rev. Immunol."},{"issue":"24","key":"55458_CR10","doi-asserted-by":"publisher","first-page":"6352","DOI":"10.3390\/cancers13246352","volume":"13","author":"M Perrone","year":"2021","unstructured":"Perrone, M., Talarico, G., Chiodoni, C. & Sangaletti, S. Impact of Immune Cell Heterogeneity on HER2\u2009+\u2009Breast Cancer Prognosis and Response to Therapy. Cancers (Basel). 13 (24), 6352. https:\/\/doi.org\/10.3390\/cancers13246352 (2021).","journal-title":"Cancers (Basel)"},{"issue":"8","key":"55458_CR11","first-page":"5039","volume":"11","author":"GL Peng","year":"2019","unstructured":"Peng, G. L. et al. CD8\u2009+\u2009cytotoxic and FoxP3\u2009+\u2009regulatory T lymphocytes serve as prognostic factors in breast cancer. Am. J. Transl Res. 11 (8), 5039\u20135053 (2019). PMID: 31497220.","journal-title":"Am. J. Transl Res."},{"issue":"24","key":"55458_CR12","doi-asserted-by":"publisher","first-page":"22196","DOI":"10.1002\/cam4.6802","volume":"12","author":"I Yilmaz","year":"2023","unstructured":"Yilmaz, I. et al. Immune checkpoint status and exhaustion-related phenotypes of CD8\u2009+\u2009T cells from the tumor-draining regional lymph nodes in breast cancer. Cancer Med. 12 (24), 22196\u201322205. https:\/\/doi.org\/10.1002\/cam4.6802 (2023).","journal-title":"Cancer Med."},{"issue":"4","key":"55458_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3892\/ol.2023.13750","volume":"25","author":"C Murazawa","year":"2023","unstructured":"Murazawa, C. et al. Status and prognostic value of immunological biomarkers of breast cancer. Oncol. Lett. 25 (4), 164. https:\/\/doi.org\/10.3892\/ol.2023.13750 (2023).","journal-title":"Oncol. Lett."},{"issue":"21","key":"55458_CR14","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1158\/1078-0432.CCR-19-3685","volume":"26","author":"ML Axelrod","year":"2020","unstructured":"Axelrod, M. L. et al. Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. Clin. Cancer Res. 26 (21), 5668\u20135681. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3685 (2020).","journal-title":"Clin. Cancer Res."},{"key":"55458_CR15","doi-asserted-by":"publisher","first-page":"e2100120","DOI":"10.1200\/PO.21.00120","volume":"6","author":"G Cai","year":"2022","unstructured":"Cai, G. et al. Circulating T-Cell Repertoires Correlate With the Tumor Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy. JCO Precis Oncol. 6, e2100120. https:\/\/doi.org\/10.1200\/PO.21.00120 (2022).","journal-title":"JCO Precis Oncol."},{"issue":"5","key":"55458_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s12282-020-01079-y","volume":"27","author":"LA Solis-Castillo","year":"2020","unstructured":"Solis-Castillo, L. A. et al. Tumor-infiltrating regulatory T cells, CD8\/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer. Breast Cancer. 27 (5), 837\u2013849. https:\/\/doi.org\/10.1007\/s12282-020-01079-y (2020).","journal-title":"Breast Cancer"},{"issue":"7","key":"55458_CR17","first-page":"3091","volume":"13","author":"XD Mao","year":"2023","unstructured":"Mao, X. D., Chen, S. Z., Shen, S. Q. & Liu, K. S. Clinical significance of regulatory T cells and T lymphocyte subsets in peripheral blood in neoadjuvant chemotherapy for breast cancer. Am. J. Cancer Res. 13 (7), 3091\u20133099. 2156-6976\/ajcr0147778 (2023).","journal-title":"Am. J. Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55458-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55458-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55458-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:07:54Z","timestamp":1786540074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55458-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55458"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55458-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25045"}}